I've sued many people, companies/corporations and a few local governments. I can't remember a case where I did not mediate before going to trial. Some were settled there and some went on. I even had one case that I won and the defendants appealed to a higher court. We then went to mediation and settled.
I agree there is something fishy going on with the shorts. The recorded number is around 27.6 million, but, I believe there may be an extra 10 to 20 million naked shorts as well. With this said, mainecoastlover1 will be verbally abusing me as soon as he reads this.
What moniker do you use at the OCAT message board? Be truthful, if that is in you. I looked back at all of your 15317 post, and all were on the GERN board and 0 on the OCAT board. You have said many times you own OCAT, yet you don't post there? Odd to say the least.
15317 posts | Last Activity: 19 minutes ago Member since: Jan 7, 2006
It will eventually be the top line treatment for Myelofibrosis. Sell SOME of your INCY and buy GERN before the news hits the streets.
It won't be long before Cramer is pumping this stock. Go GERN!
I'm ready and I've got my wallet open. Short some more, I DARE YOU!
Late-stage products expected to drive growth in the next several years, following regulatory approvals, include daratumumab for multiple myeloma; sirukumab for rheumatoid arthritis; guselkumab for psoriasis; JNJ-927 (ARN-509) for pre-metastatic prostate cancer; imetelstat for myelofibrosis; JNJ-493 (FGFRi kinase inhibitor) for urothelial cancer; esketamine for treatment-resistant depression; AL-8176 for respiratory syncytial virus (RSV); fulranumab for osteoarthritic pain; JNJ-872 (VX-787) for influenza A; JNJ-922 (Orexin-2 antagonist) for primary insomnia; and AL-335 for hepatitis C.4 In addition, daratumumab and esketamine have both received Breakthrough Therapy Designations from the U.S. Food and Drug Administration (FDA). Janssen is also announcing today that it plans to submit a Biologic Licensing Application to the FDA and a Marketing Authorization Application to the EMA this year for daratumumab in double refractory multiple myeloma. The submission will be based on Phase 2 data, which will be presented at the upcoming American Society of Clinical Oncology (ASCO) meeting.
Schubert Jonckheer & Kolbe LLP launched an investigation today into the conduct of retail pharmacies CVS and Rite Aid
Schubert Jonckheer & Kolbe LLP has launched an investigation into whether certain officers and directors of MiMedx Group, Inc. (NASDAQ: MDXG) breached their fiduciary duties to MiMedx and its shareholders.
Schubert Jonckheer & Kolbe LLP has launched an investigation into whether certain officers and directors of St. Jude Medical, Inc. STJ, +0.58% breached their fiduciary duties to St. Jude and its shareholders.
Schubert Jonckheer & Kolbe LLP is investigating potential claims on behalf of purchasers of the securities of Zynga, Inc. ("Zynga" or the "Company") (Nasdaq: ZNGA), concerning potential violations of federal securities laws and breaches of fiduciary duty by certain insiders, including Zynga’s CEO, Mark Pincu
The list goes on and on......